RS54189B1 - Postupci za korišćenje inibitora alk - Google Patents
Postupci za korišćenje inibitora alkInfo
- Publication number
- RS54189B1 RS54189B1 RS20150563A RSP20150563A RS54189B1 RS 54189 B1 RS54189 B1 RS 54189B1 RS 20150563 A RS20150563 A RS 20150563A RS P20150563 A RSP20150563 A RS P20150563A RS 54189 B1 RS54189 B1 RS 54189B1
- Authority
- RS
- Serbia
- Prior art keywords
- compound
- phenyl
- isopropoxy
- chloro
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161438878P | 2011-02-02 | 2011-02-02 | |
| PCT/US2012/023669 WO2012106540A1 (en) | 2011-02-02 | 2012-02-02 | Methods of using alk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS54189B1 true RS54189B1 (sr) | 2015-12-31 |
Family
ID=45582065
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20150563A RS54189B1 (sr) | 2011-02-02 | 2012-02-02 | Postupci za korišćenje inibitora alk |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US8703787B2 (https=) |
| EP (1) | EP2670401B1 (https=) |
| JP (1) | JP5837095B2 (https=) |
| KR (1) | KR101521861B1 (https=) |
| CN (1) | CN103458881B (https=) |
| AU (1) | AU2012212142B2 (https=) |
| BR (1) | BR112013019643B1 (https=) |
| CA (1) | CA2824092C (https=) |
| CY (1) | CY1116662T1 (https=) |
| DK (1) | DK2670401T3 (https=) |
| EA (1) | EA023404B1 (https=) |
| ES (1) | ES2543567T3 (https=) |
| HR (1) | HRP20150946T1 (https=) |
| HU (1) | HUE025395T2 (https=) |
| ME (1) | ME02200B (https=) |
| MX (1) | MX2013008791A (https=) |
| PL (1) | PL2670401T3 (https=) |
| PT (1) | PT2670401E (https=) |
| RS (1) | RS54189B1 (https=) |
| SI (1) | SI2670401T1 (https=) |
| SM (1) | SMT201500300B (https=) |
| WO (1) | WO2012106540A1 (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112015010221B1 (pt) | 2012-11-06 | 2022-09-13 | Shanghai Fochon Pharmaceutical Co., Ltd. | Inibidores de quinase alk, seus usos, composição farmacêutica, e método para fabricação de medicamento |
| WO2014074580A1 (en) * | 2012-11-07 | 2014-05-15 | Novartis Ag | Combination therapy |
| CN104109149B (zh) * | 2013-04-22 | 2018-09-28 | 苏州泽璟生物制药有限公司 | 氘代的二氨基嘧啶化合物以及包含该化合物的药物组合物 |
| ITMI20131124A1 (it) | 2013-07-04 | 2015-01-05 | Univ Milano Bicocca | 2-acilamminotiazoli per il trattamento del cancro |
| SG11201600055PA (en) * | 2013-07-11 | 2016-02-26 | Betta Pharmaceuticals Co Ltd | Protein tyrosine kinase modulators and methods of use |
| JP6479812B2 (ja) * | 2013-08-28 | 2019-03-06 | ノバルティス アーゲー | 細胞増殖性疾患を治療するためのａｌｋ阻害剤とｃｄｋ阻害剤との組合せ |
| CN104672214B (zh) * | 2013-12-03 | 2019-04-12 | 上海翰森生物医药科技有限公司 | 具有alk抑制活性的化合物及其制备与用途 |
| EP3086810A2 (en) * | 2013-12-23 | 2016-11-02 | Novartis AG | Pharmaceutical combinations |
| CN104876914B (zh) * | 2014-02-28 | 2017-04-19 | 山东轩竹医药科技有限公司 | 嘧啶衍生物类间变性淋巴瘤激酶抑制剂 |
| KR101656382B1 (ko) * | 2014-02-28 | 2016-09-09 | 한국화학연구원 | 피리미딘-2,4-디아민 유도체 및 이를 유효성분으로 함유하는 항암용 약학적 조성물 |
| CA2952787A1 (en) * | 2014-06-17 | 2015-12-23 | Korea Research Institute Of Chemical Technology | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient |
| CN105524045B (zh) * | 2014-10-22 | 2020-04-10 | 山东轩竹医药科技有限公司 | 四环类间变性淋巴瘤激酶抑制剂 |
| CN106146525B (zh) * | 2015-04-10 | 2018-11-02 | 山东轩竹医药科技有限公司 | 三并环类间变性淋巴瘤激酶抑制剂 |
| US10259816B2 (en) | 2015-04-24 | 2019-04-16 | Guangzhou Maxinovel Pharmaceuticals Co., Ltd. | Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof |
| CN106699743B (zh) | 2015-11-05 | 2020-06-12 | 湖北生物医药产业技术研究院有限公司 | 嘧啶类衍生物及其用途 |
| CN106220608B (zh) * | 2016-07-25 | 2018-11-27 | 安润医药科技（苏州）有限公司 | 二苯氨基嘧啶及三嗪化合物、其药用组合物及用途 |
| CN107698603B (zh) * | 2016-08-09 | 2022-04-08 | 南京红云生物科技有限公司 | 噻吩并嘧啶类化合物、其制备方法、药用组合物及其应用 |
| EP3504203B1 (en) * | 2016-08-29 | 2022-09-28 | The Regents of The University of Michigan | Aminopyrimidines as alk inhibitors |
| CN111484484B (zh) * | 2020-04-13 | 2021-11-23 | 沈阳药科大学 | 含芳杂环的2,4-二芳氨基嘧啶衍生物及其制备与应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| NZ585188A (en) * | 2003-08-15 | 2011-09-30 | Novartis Ag | 2,4-Pyrimidinediamines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders |
| GB0419161D0 (en) * | 2004-08-27 | 2004-09-29 | Novartis Ag | Organic compounds |
| US20090236334A1 (en) | 2006-07-10 | 2009-09-24 | Rf Dynamics Ltd | Food preparation |
| CA2598893C (en) * | 2006-10-11 | 2012-04-10 | Astellas Pharma Inc. | Eml4-alk fusion gene |
| EP2311807B1 (en) * | 2006-12-08 | 2015-11-11 | Novartis AG | Compounds and composition as protein kinase inhibitors |
| BRPI0720264B1 (pt) * | 2006-12-08 | 2022-03-03 | Novartis Ag | Compostos e composições como inibidores de proteína cinase |
| US8592432B2 (en) * | 2008-04-07 | 2013-11-26 | Bei Chen | Compounds and compositions as protein kinase inhibitors |
-
2012
- 2012-02-02 MX MX2013008791A patent/MX2013008791A/es unknown
- 2012-02-02 HU HUE12703670A patent/HUE025395T2/en unknown
- 2012-02-02 KR KR1020137023001A patent/KR101521861B1/ko active Active
- 2012-02-02 SI SI201230285T patent/SI2670401T1/sl unknown
- 2012-02-02 HR HRP20150946TT patent/HRP20150946T1/hr unknown
- 2012-02-02 WO PCT/US2012/023669 patent/WO2012106540A1/en not_active Ceased
- 2012-02-02 EP EP12703670.5A patent/EP2670401B1/en active Active
- 2012-02-02 ME MEP-2015-127A patent/ME02200B/me unknown
- 2012-02-02 PT PT127036705T patent/PT2670401E/pt unknown
- 2012-02-02 US US13/981,046 patent/US8703787B2/en active Active
- 2012-02-02 CN CN201280007465.9A patent/CN103458881B/zh active Active
- 2012-02-02 AU AU2012212142A patent/AU2012212142B2/en active Active
- 2012-02-02 EA EA201391114A patent/EA023404B1/ru not_active IP Right Cessation
- 2012-02-02 PL PL12703670T patent/PL2670401T3/pl unknown
- 2012-02-02 CA CA2824092A patent/CA2824092C/en active Active
- 2012-02-02 JP JP2013552637A patent/JP5837095B2/ja active Active
- 2012-02-02 BR BR112013019643-2A patent/BR112013019643B1/pt active IP Right Grant
- 2012-02-02 RS RS20150563A patent/RS54189B1/sr unknown
- 2012-02-02 DK DK12703670.5T patent/DK2670401T3/en active
- 2012-02-02 ES ES12703670.5T patent/ES2543567T3/es active Active
-
2015
- 2015-08-28 CY CY20151100758T patent/CY1116662T1/el unknown
- 2015-11-30 SM SM201500300T patent/SMT201500300B/it unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5837095B2 (ja) | 2015-12-24 |
| BR112013019643B1 (pt) | 2022-04-19 |
| CN103458881A (zh) | 2013-12-18 |
| PL2670401T3 (pl) | 2015-11-30 |
| ES2543567T3 (es) | 2015-08-20 |
| HUE025395T2 (en) | 2016-02-29 |
| CA2824092A1 (en) | 2012-08-09 |
| MX2013008791A (es) | 2013-10-07 |
| ME02200B (me) | 2016-02-20 |
| EP2670401A1 (en) | 2013-12-11 |
| SMT201500300B (it) | 2016-01-08 |
| HRP20150946T1 (hr) | 2015-10-09 |
| SI2670401T1 (sl) | 2015-10-30 |
| AU2012212142A1 (en) | 2013-08-15 |
| US20130296357A1 (en) | 2013-11-07 |
| JP2014504646A (ja) | 2014-02-24 |
| DK2670401T3 (en) | 2015-09-07 |
| EA023404B1 (ru) | 2016-05-31 |
| AU2012212142B2 (en) | 2015-09-24 |
| WO2012106540A1 (en) | 2012-08-09 |
| CA2824092C (en) | 2020-06-30 |
| EA201391114A1 (ru) | 2013-12-30 |
| CY1116662T1 (el) | 2017-03-15 |
| KR20130121174A (ko) | 2013-11-05 |
| CN103458881B (zh) | 2015-08-12 |
| BR112013019643A2 (pt) | 2016-10-04 |
| KR101521861B1 (ko) | 2015-05-21 |
| PT2670401E (pt) | 2015-10-12 |
| EP2670401B1 (en) | 2015-06-10 |
| US8703787B2 (en) | 2014-04-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RS54189B1 (sr) | Postupci za korišćenje inibitora alk | |
| KR102633530B1 (ko) | 혈액 장애를 치료하기 위한 화합물 및 조성물 | |
| AU2011270165B2 (en) | Antitumor agent using compounds having kinase inhibitory effect in combination | |
| AU2013289175A1 (en) | Method of treating gastrointestinal stromal tumors | |
| WO2013063003A1 (en) | Method of treating gastrointestinal stromal tumors | |
| TWI759316B (zh) | Bcl-2抑制劑及mcl1抑制劑之組合、其用途及醫藥組合物 | |
| MX2015000101A (es) | Compuestos y usos terapéuticos de los mismos. | |
| US20100041668A1 (en) | Compositions and methods for treating thrombocytopenia | |
| CN107949387A (zh) | 用谷氨酰胺酶抑制剂治疗肺癌 | |
| KR20190110581A (ko) | 암 치료 | |
| TWI741731B (zh) | 一種含西達本胺的抗腫瘤藥物組合物及其應用 | |
| CA3196283A1 (en) | Csf1r kinase inhibitor and use thereof | |
| IL302869A (en) | Methods of treating diseases and disorders | |
| AU2023202746A1 (en) | Combination of a BCL-2 inhibitor and a MCL-1 inhibitor, uses and pharmaceutical compositions thereof | |
| MXPA03009058A (es) | Uso de derivados de n-fenil-2-pirimidinamina contra desordenes alergicos tipo enfermedades basadas en mastocitos. | |
| EP4424310B1 (en) | Anti-tumor pharmaceutical composition comprising azvudine and an egfr/tki inhibitor | |
| JP6059224B2 (ja) | ピラジノ−トリアジン誘導体を含む非小細胞性肺癌の予防および治療用組成物 | |
| KR20210126654A (ko) | 암 치료 | |
| WO2020242910A1 (en) | Compositions and methods for treating cancer | |
| WO2025174879A1 (en) | Methods of reducing or eliminating measurable residual disease | |
| WO2024235217A1 (zh) | 一种抗肺癌联合用药物及其应用 | |
| HK40007956A (en) | Combination of a bcl-2 inhibitor and a mcl-1 inhibitor, uses and pharmaceutical compositions thereof | |
| HK40118235A (zh) | 用於治疗或预防癌症的喹啉衍生物 |